Wide-ranging ramifications of China’s new price regulation
This article was originally published in SRA
Executive Summary
Newly introduced controls on the retail prices of basic drugs sold in China will have broad implications for existing sales, distribution, retail and supply arrangements, say lawyers at an Australian law firm familiar with the Chinese pharmaceutical market. The lawyers, from Allens Arthur Robinson, which has offices in China, advise that the commercial basis and contractual terms for such arrangements should be carefully reviewed1.